rhNEGF
Recombinant proteinexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 22, 2019 (NCT03888053)
Timeline
Indications
Studied for
Mechanism of action
- Vascular endothelial growth factor ASupplementation
VEGFA supplementation
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06383013 | Phase 2 | Feb 29, 2024 | Blue Blood Biotech Corp., Taipei Medical University |
| NCT03888053 | Phase 1 | Mar 22, 2019 | Blue Blood Biotech Corp., National Cheng Kung University |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Blue Blood Biotech Corp. | For profit | 2 | 2 | 2 | 2019 |
| National Cheng Kung University | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Taipei Medical University | Academic/Hospital | 1 | 0 | 1 | 2024 |
3 organizations
Page 1 / 1